Fabhalta (iptacopan) slowed the decline in kidney function by 49.3% versus placebo over two years in the Phase 3 APPLAUSE IgAN study, with final results published in the New England Journal of Medicine. These definitive Phase 3 data materially strengthen the efficacy profile for Novartis’ IgAN program and could support regulatory/market uptake and upside to product revenue and share price pending approvals and commercialization.
Fabhalta (iptacopan) slowed the decline in kidney function by 49.3% versus placebo over two years in the Phase 3 APPLAUSE IgAN study, with final results published in the New England Journal of Medicine. These definitive Phase 3 data materially strengthen the efficacy profile for Novartis’ IgAN program and could support regulatory/market uptake and upside to product revenue and share price pending approvals and commercialization.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment
